 Boston Scientific Corp NYSE: BSX generated net sales of 3.026 billion in Q1 FY22, beating the Wall Street estimate of 2.95 billion. Sales increased 10 YY on a reported basis, 12.6 on an operational basis, and 9.7 on an organic basis, better than the management estimate of. 